Strattera, known by its generic name atomoxetine, is a prescription medication used to manage certain behavioral conditions. It is available in capsule form and administered orally.
Understanding Strattera’s Classification
Strattera is classified as a selective norepinephrine reuptake inhibitor, often abbreviated as SNRI. This categorization places it among medications that specifically target the reuptake of norepinephrine in the brain. Unlike some other commonly prescribed treatments, Strattera is considered a non-stimulant medication. This means it does not fall under the same regulatory classifications as stimulant drugs. Its non-stimulant nature is a significant aspect of its classification within the pharmacological landscape.
How Strattera Works
Strattera selectively inhibits the presynaptic norepinephrine transporter (NET). This prevents the reabsorption of norepinephrine back into the neuron, leading to increased concentrations of this neurotransmitter in the synaptic cleft, which is the space between nerve cells. While its primary focus is on norepinephrine, atomoxetine also indirectly increases dopamine levels in the prefrontal cortex, a brain region involved in executive functions. This elevation of norepinephrine and dopamine in specific brain areas is believed to contribute to Strattera’s therapeutic effects, helping to improve attention and reduce impulsivity. The full therapeutic benefits of Strattera may take typically 4 to 6 weeks to become apparent with consistent daily use.
Distinction from Stimulant Medications
Strattera stands apart from traditional stimulant medications like methylphenidate (e.g., Ritalin) and amphetamines (e.g., Adderall, Vyvanse) due to its different mechanism and classification. Stimulants primarily work by increasing the availability of both dopamine and norepinephrine throughout the brain. In contrast, Strattera’s action is more selective, focusing mainly on norepinephrine reuptake and indirectly influencing dopamine in the prefrontal cortex, rather than broadly increasing dopamine in reward centers. Stimulants generally have a more immediate onset of action, with effects often felt within 30 to 60 minutes, while Strattera requires daily administration and a longer period to reach its full effectiveness. Furthermore, stimulant medications are classified as Schedule II controlled substances due to their potential for misuse and dependence, whereas Strattera is not a controlled substance and has a lower risk of abuse, making it an alternative for individuals who may not tolerate stimulant side effects or have substance use concerns.
Conditions Treated with Strattera
Strattera is primarily prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in various age groups. It is approved for use in children aged six years and older, adolescents, and adults. For some individuals, particularly those who do not respond well to stimulant medications or experience intolerable side effects, Strattera offers an alternative treatment path. It can also be considered for patients with co-existing conditions, such as anxiety or depression, as it may have properties that help with these symptoms, though it is not a primary treatment for depression. Its use is part of a comprehensive treatment plan that may include other interventions like behavioral therapy.